Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Visit NurExone Biologic Inc.

NurExone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.



Bullboard - Investor Discussion Forum NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following... see more

Bullboard (TSXV:NRX)

View:
Prev 1 2 3 4 Next
Post by Oldschool2022on Feb 09, 2024 6:15am

Up 42.7% on the Frankfurt over night trading.

This rocket has launched. Last trading at .645 Euros or .93 Canadian. Can we make this the 5th straight green day this week? News has to be close. Their spinal therapy is world changing. Hold tight ...more  
128
Post by Oldschool2022on Feb 08, 2024 10:34pm

Litchfield Hills research has a $4 price target on NurExone

We should easily hit 1.20-$1.30 tomorrow. The trend is your friend. Looking at the chart something big is coming. This could keep moving for a few weeks. Wouldn't that be nice.
71
Post by Oldschool2022on Feb 08, 2024 8:57pm

This stock has moved from .32 to .83 per share in 2 days.

Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX) January 22, 2024 at 05:01 am EST  Share (via NewsDirect) Investors eyeing dynamic opportunities in healthcare ...more  
166
Post by ElliotGHon Feb 05, 2024 12:16pm

$NRX gains traction in Europe with Orphan drug designation

NurExone gains traction in Europe with Orphan drug designation awarded by regulator (TSXV: NRX) (FSE: J90) (NRX.V)   https://10xalerts.com/nurexone-gains-traction-in-europe-with-orphan-drug ...more  
83
Post by Brice978on Jan 22, 2024 2:02pm

Top 4 Spinal Injury Stocks for 2024 ((TSXV: NRX, NYSE: NVRO,

Top 4 Spinal Injury Stocks for 2024 ((TSXV: NRX, NYSE: NVRO, NYSE: SYK, NYSE: BSX)  https://www.marketscreener.com/quote/stock/NUREXONE-BIOLOGIC-INC-49479308/news/Top-4-Spinal-Injury-Stocks-for ...more  
100
Post by Mathew177on Jan 16, 2024 11:28am

NurExone Biologic Inc is Poised to Capture Significant Value

NurExone Biologic Inc. is Poised to Capture Significant Value (TSXV: NRX) (FSE: J90) (NRX.V)   https://10xalerts.com/nurexone-biologic-inc-is-poised-to-capture-significant-value-tsxv-nrx-fse ...more  
111
Discussion
Post by RealREIT$on Dec 01, 2023 11:59am

New Highs

Hitting $0.315 now from $0.18 when I got in. Should hit $0.345 next...
113
Comment by RealREIT$on Nov 30, 2023 3:20pm

RE:Undervalued Israeli Biotech : NurExone Biologic Inc

This should see a lot more attention with their developments. Orphan Drug Designation should have boosted this to $0.50 easily. 
75
Discussion
Post by Brice978on Nov 28, 2023 3:00pm

Undervalued Israeli Biotech : NurExone Biologic Inc

Undervalued Israeli Biotech : NurExone Biologic Inc (TSXV: NRX) https://10xalerts.com/undervalued-israeli-biotech-nurexone-biologic-inc-tsxv-nrx/
130
Discussion
Post by Nibinatoron Oct 30, 2023 4:50pm

Potential market disrupter

Even for alzeimer and dementia i suppose
118
Comment by RealREIT$on Oct 30, 2023 1:15pm

RE:NurExone Biologic Receives FDA Orphan-Drug Designation

https://www.americangene.com/blog/benefits-of-fda-orphan-drug-designation-what-you-need-to-know/
90
Discussion
Post by RealREIT$on Oct 30, 2023 1:11pm

NurExone Biologic Receives FDA Orphan-Drug Designation

https://www.globenewswire.com/news-release/2023/10/30/2769335/0/en/NurExone-Biologic-Receives-FDA-Orphan-Drug-Designation-Accelerating-Development-of-ExoPTEN-therapy-for-Acute-Spinal-Cord-Injury ...more  
115
Discussion
Prev 1 2 3 4 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.NRX

Visit Facebook Visit X Visit Linked In Visit Youtube



PRESENTATION TECHNOLOGY - EXOSOMES TECHNOLOGY - EXOTHERAPY MANAGEMENT ANALYST REPORT LEARN ABOUT ODD

Investor Presentation

View the Presentation

Investment Opportunity

NurExone operates according to two business lines – Development of a first exosome-based therapy for acute Spinal Cord Injuries (SCI).

In parallel, the company is monetizing its proprietary ExoTherapy platform through licensing to the global biopharmaceutical industry to deliver therapies for other diseases and indications.

The company’s first product, ExoPTEN, for acute spinal cord injury, has been granted Orphan Drug Designation by the FDA.



Why NurExone??

The Ultimate Drug Delivery System

The Beginning of NurExone

Facebook

Contact Us

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu